<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_SYSU-MEDICINE_Legislation skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:SYSU-MEDICINE/Legislation</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="container-fluid"><DIV class="navbar-header"><BUTTON type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#bs-example-navbar-collapse-1" aria-expanded="false"><SPAN class="sr-only">Toggle navigation</SPAN></BUTTON><A class="navbar-brand" href="https://2016.igem.org/Team:SYSU-MEDICINE">SYSU-MEDICINE</A></DIV><DIV class="collapse navbar-collapse" id="bs-example-navbar-collapse-1"><UL class="nav navbar-nav navbar-right"><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE">HOME</A></LI><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">PROJECT</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Description">Description</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Results">Results</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Protocol">Protocol</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Notebook">Notebook</A></LI><LI class="dropdown third-level-menu"><A href="#" class="dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">For Judgement </A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Proof">Proof of Concept</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Demonstrate">Demonstrate</A></LI></UL><LI class="dropdown active"><A href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">HUMAN PRACTICES</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Our_Story">Our Story</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Interview">Interview</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Ethics">Ethics</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Legislation">Legislation</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Products">Products</A></LI><LI class="dropdown third-level-menu"><A href="#" class="dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">For Judgement </A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/HP/Silver">Silver</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/HP/Gold">Gold</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Integrated_Practices">Integrated Practices</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Engagement">Engagement</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Modeling">MODELING</A></LI><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">TEAM</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Team">Team</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Attributions">Attributions</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Collaborations">Collaborations</A></LI><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">PARTS</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Parts">Parts</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Basic_Part">Basic Parts</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Composite_Part">Composite Parts</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Part_Collection">Part Collection</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Safety">SAFETY</A></LI><LI><A href="https://2016.igem.org/Team:SYSU-MEDICINE/Judging">JUDGING</A></LI></DIV></DIV><DIV class="jumbotron"><DIV class="my-content" style="width:1070px;"><H1 align="center">Law and Regulation </H1></DIV></DIV><DIV class="jumbotron" id="content"><DIV class="my-content"><H2>Administration measures of different countries</H2><P>
            Law and Regulation are the vital factors of our product – MSCs preparation. During the research of clinical trials, we found that several scientist teams have finished clinical trials in China. As we all know that there have existed about 10 MSCs drugs in the world by now, but none of them is approved in China, which confused us that why there is no MSCs product approved in China. We investigated the administration measures of different countries and compared them with that of China, and asked legislation experts some questions during the meeting, hoping to know how far our project would go and find a proper way for development of MSCs therapy in China.<B>1.	America</B>
             	Laws
            -	Current Good Tissue Practice (cGTP)
            -	Current Good Manufacture Practice (cGMP) 
             	Sort management by the risk of cell/tissue products<B>2.	European Medicines Agency (EMA)</B>
             	Laws
            -	Standards of Quality and Safety for the Donation, Procurement, Testing, Processing, Reservation, Storage and Distribution of Human Tissue and Cells
            -	Regulation of Advanced Therapy Medicinal Products
             	EMA focus on the common characteristic of Advanced Therapy Medicinal Products:
            -	Complex and high creative process
            -	Special producing process
            -	Rare experts can assess it
            -	Can trace back to the donator
            -	Still high risk after approval
            -	Need long-term observation
            -	Middle or small institution can carry out
            -	Belong to fast creative field<B>3.	Australia</B>
             	Laws
            -	In 2002, the Meeting of Ministers of Health agreed Therapeutic Goods Administration (TGA) to enact guideline of cell and tissue therapy<B>4.	Korea</B>
             	Laws
            -	In 2011，Good Manufacture Practice was carried out
             	Cell therapy products administrated by Ministry of Food and Drug Safety <B>5.	Japan</B>
             	Laws
            -	Guidelines on Ensuring the Quality and Safety of Products Derived from Processed Cell/Tissue
             	Two pathways for development of cell therapy<B>6.	China</B>
             	Technic or Medicine?<B>What happened in 2012?</B>
            -	Stem cell black market: As we all know that clinical trials are forbidden to charge the patients, but a few hospitals over-advertised the effect of stem cell therapy and even charged the patients, which causing severe effect to the society. <B>The Death of Wei Zexi</B>
            -	Wei Zexi was a 21-year old Chinese college student from Shaanxi who died after receiving experimental immunization therapy treatment for synovial sarcoma at the Second Hospital of the Beijing Armed Police Corps. One of the serious influences of his death is the halt of all stem cell clinical research over China.<B>Reference：</B>
            http://www.fda.gov
            http://www.ema.europa.eu/ema/
            https://www.tga.gov.au
            http://eng.kfda.go.kr/index.html
            http://www.mhlw.go.jp/english/
            http://www.nhfpc.gov.cn
            http://www.sda.gov.cn</P><H2>
            Different countries have different attitudes toward MSCs therapy
        </H2><P>
            In the European Union, stem cell research using the human embryo is permitted in Sweden, Finland, Belgium, Greece, Britain, Denmark and the Netherlands; however, it is illegal in Germany, Austria, Ireland, Italy, and Portugal. The issue has similarly divided the United States, with several states enforcing a complete ban and others giving financial support. Elsewhere, Japan, India, Iran, Israel, South Korea, and Australia are supportive. However, New Zealand, most of Africa (except South Africa), and most of South America (except Brazil) are restrictive.
            Reference:
            https://en.wikipedia.org/wiki/Stem_cell_laws
            http://www.explorestemcells.co.uk/stemcellresearcharoundworld.html</P><H2>
            What’s More
        </H2><P>
            We attended Guangdong Cell Therapy Annual Meeting and learn much more about MSCs legislation. <A target="_blank" href="https://2016.igem.org/Team:SYSU-MEDICINE/Interview#laws">More</A></P></DIV></DIV><DIV class="jumbotron" id="jumbo-footer"><DIV class="footer-container"><DIV class="title">
            Contact us
        </DIV><DIV class="contact"><UL class="float-contact"><LI><A href="http://weibo.com/u/5999650333">
                        iGEMxSYSU-MEDICINE
                    </A></LI><LI><A href="https://www.facebook.com/IGEM-SYSU-Medicine">
                        IGEM SYSU-Medicine
                    </A></LI><LI><A href="#">
                        SYSU_MEDICINE@163.com
                    </A></LI></UL><UL class="float-contact"><LI><A href="#" data-toggle="modal" data-target="#wechatModal">
                        SYSU-MEDICINE
                    </A></LI><LI><A href="https://twitter.com/IgemSysu">
                        iGEM SYSU-MEDICINE
                    </A></LI></UL></DIV><DIV class="copyright"><DIV class="text">© 2016 SYSU-MEDICINE. All Rights Reserved.
            </DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>